Henkel Facilities Secure EXCiPACT Certificate For Pharmaceutical Excipient Quality

Henkel Adhesive Technologies, a global leader in the production of acrylic polymers for transdermal drug delivery, has once again been recognized for its commitment to quality. The company's facility in Salisbury, North Carolina, has received the EXCiPACT certificate, marking a significant achievement in the pharmaceutical industry. This follows the certification of Henkel's Drogenbos site in Belgium, which has held the EXCiPACT certification since 2021.

The EXCiPACT certification is a testament to Henkel's adherence to the stringent guidelines for good manufacturing practice (GMP) and good distribution practice (GDP) set by the non-profit organization. This certification is crucial as it is acknowledged by major stakeholders in the pharmaceutical industry, including the European Union, the US Food and Drug Administration, and the British Medicines and Healthcare products Regulatory Agency (MHRA).

Henkel's expertise in polymerization spans over six decades, making it a pioneer in the field. The company specializes in producing pressure-sensitive adhesives (PSAs) and polyisobutylene (PIB), which are essential components in transdermal drug delivery systems such as patches, medical adhesives for wound care, drug coatings, and pharmaceutical packaging materials.

The company offers an extensive range of more than 25 excipients used in the pharmaceutical industry. Its acrylic adhesives, Duro-Tak and Gelva, are integral to over 50 approved patches distributed globally. These products are known for their skin-friendliness, strong adhesion properties, and versatile solubility characteristics suitable for a wide array of drugs.

Nilhan Savant Kayaci, Global Director of Drug Delivery Polymers at Henkel, emphasized the importance of the EXCiPACT certificate in reinforcing customer trust. "For many years now, we have been an active member of IPEC-Americas, an association that develops quality, safety and functionality standards for the pharmaceutical industry. The EXCiPACT certificate sends another strong signal to our customers that we are meeting the standards required by the pharmaceutical industry," Kayaci stated.

The Salisbury and Drogenbos facilities serve as key production sites for Henkel Adhesive Technologies, catering to North America and Europe—two dominant markets in the pharmaceutical sector. According to Vijay Ramachandran, Vice President Key Accounts North America at Henkel Adhesive Technologies, both sites currently meet global demand for PSAs under IPEC-GMP guidelines. The company also plans to expand its business to other regions, including Asia-Pacific.

This certification not only underscores Henkel's leading role in excipient production but also its dedication to manufacturing high-quality products that meet global standards. As Henkel continues to innovate and expand its reach in the pharmaceutical industry, its commitment to quality remains unwavering.